WallStreetZenWallStreetZen

NASDAQ: APRE
Aprea Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for APRE

Based on 3 analysts offering 12 month price targets for Aprea Therapeutics Inc

Min Forecast
$1.20+57.89%
Avg Forecast
$3.07+303.55%
Max Forecast
$5.00+557.89%

Should I buy or sell APRE stock?

Based on 3 analysts offering ratings for Aprea Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their APRE stock forecasts and price targets.

APRE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-13
lockedlocked$00.00+00.00%2026-05-07
lockedlocked$00.00+00.00%2026-03-31

1 of 1

Forecast return on equity

Is APRE forecast to generate an efficient return?

Company
-10.68%
Industry
21.25%
Market
168.71%
APRE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is APRE forecast to generate an efficient return on assets?

Company
-9.72%
Industry
23.75%
APRE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

APRE earnings per share forecast

What is APRE's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.40
Avg 2 year Forecast
-$0.35
Avg 3 year Forecast
-$0.34

APRE revenue forecast

What is APRE's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%
APRE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

APRE revenue growth forecast

How is APRE forecast to perform vs Biotechnology companies and vs the US market?

Company
-100%
Industry
32.77%
Market
13.78%
APRE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
APRE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

APRE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
APRE$0.76$3.07+303.55%Buy
FBLG$1.43$6.00+319.58%Hold
IMRN$1.22N/AN/A
SNTI$0.32$12.00+3,650.00%Strong Buy
ALZN$1.89$26.00+1,275.66%Buy
View Top Biotech Stocks

Aprea Therapeutics Stock Forecast FAQ

Is Aprea Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: APRE) stock is to Buy APRE stock.

Out of 3 analysts, 0 (0%) are recommending APRE as a Strong Buy, 3 (100%) are recommending APRE as a Buy, 0 (0%) are recommending APRE as a Hold, 0 (0%) are recommending APRE as a Sell, and 0 (0%) are recommending APRE as a Strong Sell.

If you're new to stock investing, here's how to buy Aprea Therapeutics stock.

What is APRE's earnings growth forecast for 2026-2028?

(NASDAQ: APRE) Aprea Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.

Aprea Therapeutics's earnings in 2026 is -$12,307,261.On average, 6 Wall Street analysts forecast APRE's earnings for 2026 to be -$5,008,754, with the lowest APRE earnings forecast at -$7,403,588, and the highest APRE earnings forecast at -$3,701,794. On average, 6 Wall Street analysts forecast APRE's earnings for 2027 to be -$4,399,343, with the lowest APRE earnings forecast at -$5,922,870, and the highest APRE earnings forecast at -$2,776,345.

In 2028, APRE is forecast to generate -$4,270,913 in earnings, with the lowest earnings forecast at -$5,676,084 and the highest earnings forecast at -$2,511,932.

What is APRE's revenue growth forecast for 2026-2028?

(NASDAQ: APRE) Aprea Therapeutics's forecast annual revenue growth rate of -100% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.

Aprea Therapeutics's revenue in 2026 is $5,185.On average, 5 Wall Street analysts forecast APRE's revenue for 2026 to be $0, with the lowest APRE revenue forecast at $0, and the highest APRE revenue forecast at $0. On average, 5 Wall Street analysts forecast APRE's revenue for 2027 to be $0, with the lowest APRE revenue forecast at $0, and the highest APRE revenue forecast at $0.

In 2028, APRE is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is APRE's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: APRE) forecast ROA is -9.72%, which is lower than the forecast US Biotechnology industry average of 23.75%.

What is APRE's Price Target?

According to 3 Wall Street analysts that have issued a 1 year APRE price target, the average APRE price target is $3.07, with the highest APRE stock price forecast at $5.00 and the lowest APRE stock price forecast at $1.20.

On average, Wall Street analysts predict that Aprea Therapeutics's share price could reach $3.07 by Aug 13, 2027. The average Aprea Therapeutics stock price prediction forecasts a potential upside of 303.55% from the current APRE share price of $0.76.

What is APRE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: APRE) Aprea Therapeutics's current Earnings Per Share (EPS) is -$1.04. On average, analysts forecast that APRE's EPS will be -$0.40 for 2026, with the lowest EPS forecast at -$0.59, and the highest EPS forecast at -$0.29. On average, analysts forecast that APRE's EPS will be -$0.35 for 2027, with the lowest EPS forecast at -$0.47, and the highest EPS forecast at -$0.22. In 2028, APRE's EPS is forecast to hit -$0.34 (min: -$0.45, max: -$0.20).

What is APRE's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: APRE) forecast ROE is -10.68%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.